Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
Anavex Life Sciences (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, will release its fiscal 2025 second quarter financial results on Tuesday, May 13, 2025. The company will host a conference call and webcast at 8:30 am ET the same day, where management will discuss financial results and provide updates on the company's growth strategy.
Anavex focuses on developing innovative treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other neurodegenerative and rare diseases. The conference call will be accessible via webcast on www.anavex.com or by phone for U.S. participants at 1-929-205-6099 using Meeting ID# 856 5033 5285 and passcode 014 352. A replay will be available on the company's website for up to 30 days.
Anavex Life Sciences (Nasdaq: AVXL), una società biofarmaceutica in fase clinica, pubblicherà i risultati finanziari del secondo trimestre fiscale 2025 il martedì 13 maggio 2025. La società terrà una conference call e una webcast lo stesso giorno alle 8:30 am ET, durante le quali il management discuterà i risultati finanziari e fornirà aggiornamenti sulla strategia di crescita aziendale.
Anavex è focalizzata sullo sviluppo di trattamenti innovativi per diversi disturbi del sistema nervoso centrale, tra cui morbo di Alzheimer, morbo di Parkinson, schizofrenia, sindrome di Rett e altre malattie neurodegenerative e rare. La conference call sarà accessibile in webcast su www.anavex.com o telefonicamente per i partecipanti negli Stati Uniti al numero 1-929-205-6099, utilizzando Meeting ID# 856 5033 5285 e passcode 014 352. La registrazione sarà disponibile sul sito web della società per un massimo di 30 giorni.
Anavex Life Sciences (Nasdaq: AVXL), una compañía biofarmacéutica en etapa clínica, publicará sus resultados financieros del segundo trimestre fiscal 2025 el martes 13 de mayo de 2025. La empresa realizará una llamada conferencia y una transmisión en vivo el mismo día a las 8:30 am ET, donde la dirección discutirá los resultados financieros y proporcionará actualizaciones sobre la estrategia de crecimiento de la compañía.
Anavex se centra en desarrollar tratamientos innovadores para diversos trastornos del sistema nervioso central, incluyendo enfermedad de Alzheimer, enfermedad de Parkinson, esquizofrenia, síndrome de Rett y otras enfermedades neurodegenerativas y raras. La llamada conferencia será accesible vía webcast en www.anavex.com o por teléfono para participantes en EE. UU. al 1-929-205-6099 usando el ID de reunión 856 5033 5285 y la contraseña 014 352. Una repetición estará disponible en el sitio web de la compañía durante hasta 30 días.
Anavex Life Sciences (나스닥: AVXL)는 임상 단계의 바이오제약 회사로, 2025 회계연도 2분기 재무 결과를 2025년 5월 13일 화요일에 발표할 예정입니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 컨퍼런스 콜 및 웹캐스트를 진행하며, 경영진이 재무 결과를 논의하고 회사의 성장 전략에 대한 업데이트를 제공할 것입니다.
Anavex는 알츠하이머병, 파킨슨병, 조현병, 레트 증후군 등 다양한 중추신경계 질환 및 기타 신경퇴행성 및 희귀 질환에 대한 혁신적인 치료법 개발에 집중하고 있습니다. 컨퍼런스 콜은 www.anavex.com에서 웹캐스트로 접속하거나 미국 참가자는 1-929-205-6099번으로 전화하여 회의 ID# 856 5033 5285와 비밀번호 014 352를 사용해 참여할 수 있습니다. 재방송은 회사 웹사이트에서 최대 30일간 제공됩니다.
Anavex Life Sciences (Nasdaq : AVXL), une société biopharmaceutique en phase clinique, publiera ses résultats financiers du deuxième trimestre fiscal 2025 le mardi 13 mai 2025. La société tiendra une conférence téléphonique et une webdiffusion le même jour à 8h30 ET, où la direction discutera des résultats financiers et fournira des mises à jour sur la stratégie de croissance de l'entreprise.
Anavex se concentre sur le développement de traitements innovants pour divers troubles du système nerveux central, notamment la maladie d'Alzheimer, la maladie de Parkinson, la schizophrénie, le syndrome de Rett et d'autres maladies neurodégénératives et rares. La conférence téléphonique sera accessible via webcast sur www.anavex.com ou par téléphone pour les participants américains au 1-929-205-6099 en utilisant l'ID de réunion 856 5033 5285 et le code d'accès 014 352. Une rediffusion sera disponible sur le site de la société pendant 30 jours maximum.
Anavex Life Sciences (Nasdaq: AVXL), ein biopharmazeutisches Unternehmen in der klinischen Phase, wird die Finanzergebnisse für das zweite Quartal des Geschäftsjahres 2025 am Dienstag, den 13. Mai 2025 veröffentlichen. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, bei denen das Management die Finanzergebnisse besprechen und Updates zur Wachstumsstrategie des Unternehmens geben wird.
Anavex konzentriert sich auf die Entwicklung innovativer Behandlungen für verschiedene Erkrankungen des zentralen Nervensystems, darunter Alzheimer-Krankheit, Parkinson-Krankheit, Schizophrenie, Rett-Syndrom sowie andere neurodegenerative und seltene Erkrankungen. Die Telefonkonferenz ist per Webcast auf www.anavex.com oder telefonisch für US-Teilnehmer unter 1-929-205-6099 mit der Meeting-ID 856 5033 5285 und dem Passwort 014 352 zugänglich. Eine Aufzeichnung wird bis zu 30 Tage auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its second fiscal quarter on Tuesday , May 13, 2025.
Management will host a conference call on Tuesday, May 13, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy. Following management’s remarks, there will be a question-and-answer session.
Webcast / Conference Call Information:
The live webcast of the conference call will be available on Anavex’s website at www.anavex.com.
The conference call can be also accessed by dialing 1 929 205 6099 for participants in the U.S. using the Meeting ID# 856 5033 5285 and reference passcode 014 352. A replay of the conference call will also be available on Anavex’s website for up to 30 days.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
When will AVXL report its Q2 2025 financial results?
How can investors access AVXL's Q2 2025 earnings call?
What diseases is Anavex Life Sciences focusing on treating?
How long will the replay of AVXL's Q2 2025 earnings call be available?
